|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, May 17, 2008 ) DALLAS, TX – HemoBioTech, Inc. (OTCBB: HMBT - News, http://www.hemobiotech.com) announced today that it received an exclusive worldwide license from Texas Tech University System for a new technology that addresses the safety of animal-derived products for human use in pharmaceutical, cosmetic and other industries. This new technology could prevent the spread of transmissible spongiform encephalopathies ("TSE"), also know as prions or mad cow disease, as well as viruses. The Food and Drug Administration ("FDA") strictly regulates medicinal products and cosmetics that contain ingredients from animals, particularly of bovine origin. The technology is being used in the manufacturing of HemoBioTech’s lead product HemoTech, potentially the first viable substitute for human blood. HemoTech is composed of chemically modified bovine hemoglobin.
The new purification technology, called "Orthogonal Method for the Removal of Transmissible Spongiform Encephalopathy Agents from Biological Fluids," could allow robust and reliable elimination of infectious agents, such as prions and viruses from the final product, using independent clearance steps, inactivation and removal.
This is a critical purification process in enhancing the safety that is needed for approval to sell such products. The market for pharmaceutical and cosmetic products for human use derived from animals is in excess of $7 billion.
"We are very excited about licensing this important technology. The goal is not only to use it for the manufacturing of our HemoTech but also to sublicense it to pharmaceutical, biotech, cosmetic and other companies that use animal-derived products for a variety of human uses. There is a continuing need to optimize the safety of such products for human use," said Dr. Arthur P. Bollon, chairman & CEO of HemoBioTech, Inc.
Texas Tech University Health Sciences Center scientists, Dr. Jan Simoni, Grace Simoni, and Dr. John F. Moeller developed this technology. The inventors will work with HemoBioTech in interacting with potential partners for sub-licensing opportunities.
Dr. Jan Simoni, Professor of Research at the Texas Tech Department of Surgery states, "This orthogonal technology could be effective in the elimination of pathogens from hemoglobin, which is susceptible for degradation, and also from other animal-derived products with therapeutic or cosmetic value in humans. Since this technology could also be used for clearance of pathogens of human origin, similar measures may apply for pharmaceuticals derived from human tissue. We are looking forward to introducing this technology to the industry to enhance the safety of biopharmaceuticals and cosmetics."
About HemoBioTech, Inc.
HemoBioTech is engaged in the commercial development of HemoTech, a novel human blood substitute technology developed by Texas Tech University Health Sciences Center scientists, Drs. Mario Feola and Jan Simoni, and exclusively licensed from Texas Tech University System. HemoTech is composed of bovine hemoglobin that is chemically modified with ATP, Adenosine and GSH. HemoTech not only can carry oxygen in the blood, but can also induce erythropoiesis (red blood cell production). The Company believes that HemoTech, due to its novel structure, may possess properties that diminish the intrinsic toxicities that have plagued other attempts at developing blood substitutes, based upon pre-clinical and initial human clinical trials undertaken outside the U.S.. HemoTech is being subjected to further studies and testing to confirm and possibly expand on these results. HemoTech is being developed to help reduce or eliminate the danger resulting from acute blood loss in trauma, as well as for other conditions.
Corporate headquarters are located at 5001 Spring Valley Road, Suite 1040-West, Dallas, Texas 75244. For further information contact, Dr. Arthur Bollon at: 972-455-8955 or arthurb@flash.net or visit our website at: http://www.hemobiotech.com.
Safe Harbor Statement
Except for historical information, the matters discussed in this news release may be considered "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of HemoBioTech and its management and are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others the successful pre- clinical development, the successful completion of clinical trials, the FDA review process and other governmental regulation, pharmaceutical collaborator interest and ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors which are included in HemoBioTech's Annual Report on Form 10-K for the year ending December 31, 2007, as amended, and HemoBioTech's other reports filed with the Securities and Exchange Commission.
Contact:
HemoBioTech, Inc.
Arthur P. Bollon, PhD,
972-455-8950
Chairman & CEO
abollon@hemobiotech.com
or
The Investor Relations Group, Inc.
212-825-3210
Investor Relations:
Christine Berni / Conrad F. Mir
212-825-3210
christine@investorrelationsgroup.com
conrad@investorrelationsgroup.com
or
Media:
Hayden Lynch / Janet Vasquez
hayden@investorrelationsgroup.com
janet@investorrelationsgroup.com
###
This press release was issued through GroupWeb EmailWire.Com. For more information on unlimited press release distribution service, go to http://www.emailwire.com
HemoBioTech, Inc.
Arthur P. Bollon, PhD,
972-455-8950
abollon@hemobiotech.com 
Source: EmailWire.com
|
|
|
|
